Regeneron Pharmaceuticals, Inc.
IL-2 VARIANTS WITH REDUCED BINDING TO IL-2 RECEPTOR ALPHA AND USES THEREOF

Abstract:

This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R.alpha.. The IL-2 variants may retain the ability in binding to or activating IL-2R.beta. and/or IL-2R.beta..gamma.. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.